Internal medicine

Vemurafenib

Melanoma

Dabrafenib

Overall survival

Biology

Oncology

Stage (stratigraphy)

Paleontology

Kinase

Trametinib

Chemotherapy

Adjuvant

Adjuvant therapy

MAPK/ERK pathway

Cell biology

Metastatic melanoma

Cancer research

Medicine

New England Journal of Medicine

In the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations. To confirm the stability of the relapse-free survival benefit, longer-term data were needed.

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma